Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: a case report

Tools
- Tools
+ Tools

Bhattacharya, Sayantan, Choudhury, Amit Kumar, Ravi, Srinivasan, Morrissey, John R. and Mathew, G. (George) (2008) Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: a case report. Journal of Medical Case Reports, Vol.2 (No.110). doi:10.1186/1752-1947-2-110 ISSN 1752-1947.

[img]
Preview
PDF
WRAP_Morrisey_Six_years.pdf - Requires a PDF viewer.

Download (671Kb)
Official URL: http://dx.doi.org/10.1186/1752-1947-2-110

Request Changes to record.

Abstract

Introduction: A duodenal Gastrointestinal Stromal Tumour (GIST) is a rare finding and until recently advanced disease had a poor prognosis. A PubMed search revealed no reports of more than five years survival of inoperable GIST on chemotherapy with WHO performance status zero.
Case Presentation: A 68 year old female was diagnosed with unresectable GIST in the duodenum with metastasis to liver, pancreas and omentum in November 2001. She was
commenced on imatinib mesylate (Glivec) chemotherapy. This case report was prepared from the medical records and radiology reports. She had good tolerance with stable disease. After six years her CT scan showed no disease progression and her WHO performance status was zero.
Conclusion: This report supports the view that imatinib is a safe and effective drug in controlling
disease progression in advanced metastatic GIST and plays an important role in improving the patient's quality of life.

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Duodenum -- Diseases, Gastrointestinal stronal tumours, Chemotherapy
Journal or Publication Title: Journal of Medical Case Reports
Publisher: BioMed Central Ltd.
ISSN: 1752-1947
Official Date: 18 April 2008
Dates:
DateEvent
18 April 2008Published
Volume: Vol.2
Number: No.110
DOI: 10.1186/1752-1947-2-110
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access (Creative Commons)
Related URLs:
  • Organisation

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us